Product image of Nocdurna (Desmopressin) supplied by GNH India

Nocdurna

Active Ingredient:
Desmopressin
Origin:
EU

Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a sublingual formulation for sublingual use. It mimics the natural antidiuretic hormone to reduce excessive urine output and to promote clotting factor stability, and it is employed to manage central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as mild hemophilia A and von Willebrand disease.

GNH India supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ferring N.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Desmopressin acts on the antidiuretic hormone pathway to regulate water balance and coagulation.

  • Central diabetes insipidus: reduces polyuria and concentrates urine, helping maintain fluid balance.
  • Nocturnal enuresis: decreases nighttime urine production, reducing bedwetting episodes.
  • Mild hemophilia A and von Willebrand disease: raises plasma levels of factor VIII and von Willebrand factor, improving clot formation.

How It Works

  • Desmopressin is a synthetic analogue of vasopressin that selectively binds to V2 receptors on the basolateral membrane of renal collecting‑duct cells. Receptor activation stimulates adenylate cyclase, raising intracellular cAMP and promoting insertion of aquaporin‑2 channels into the apical membrane, which enhances water reabsorption. The same V2 activation in endothelial cells triggers release of von Willebrand factor and factor VIII, supporting haemostatic function.

Side Effects

Desmopressin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Headache: mild to moderate pain in the head.
  • Nausea: upset stomach or feeling of queasiness.
  • Nasal congestion: sensation of a blocked nose.
  • Mild hyponatremia: slight reduction in serum sodium, often asymptomatic.

Serious or Rare Side Effects

  • Severe hyponatremia with seizures: marked sodium drop leading to neurological symptoms.
  • Thromboembolic events: rare formation of blood clots.
  • Allergic reactions: rash, itching, swelling, or other hypersensitivity signs.

Precautions & Warnings

When prescribing Nocdurna, clinicians should consider several safety measures.

  • Dose titration: adjust dose based on urine output and serum sodium levels.
  • Fluid restriction: limit excessive water intake to reduce hyponatremia risk.
  • Monitor electrolytes: regularly check serum sodium during therapy.
  • Cardiovascular disease: use caution in patients with heart failure or hypertension.
  • Pregnancy and lactation: evaluate risk–benefit as safety data are limited.
  • Store at room temperature: keep below 25°C in original packaging, protect from moisture.

Avoid Interactions

Desmopressin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Thiazide diuretics: may exacerbate hyponatremia.
  • NSAIDs (e.g., ibuprofen): can potentiate antidiuretic effect and increase water retention.
  • Other antidiuretic agents (e.g., carbamazepine): additive risk of low sodium.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): desmopressin may enhance clotting factor levels, affecting monitoring.
  • SSRIs (e.g., fluoxetine): possible increased risk of hyponatremia.
  • Alcohol: may potentiate central nervous system effects.

Frequently Asked Questions

Nocdurna, containing desmopressin, is prescribed for central diabetes insipidus to control excessive urination, for nocturnal enuresis to reduce nighttime bedwetting, and for certain bleeding disorders such as mild hemophilia A and von Willebrand disease to increase clotting factor levels.

Desmopressin is a synthetic vasopressin analogue that selectively stimulates V2 receptors in the kidney’s collecting ducts. This activation raises cyclic AMP, causing aquaporin‑2 water channels to move to the cell surface, which enhances water reabsorption and concentrates urine. In endothelial cells, V2 activation promotes release of von Willebrand factor and factor VIII, aiding haemostasis.

The appropriate dose of Nocdurna is individualized by the prescribing clinician based on the patient’s specific condition, urine output, serum sodium concentration, and response to therapy. Dosage adjustments are made according to clinical monitoring rather than a fixed regimen.

Safety data for desmopressin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To request Nocdurna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nocdurna (desmopressin) is a selective V2‑receptor agonist, offering a more targeted antidiuretic effect than non‑selective agents such as vasopressin. Its sublingual route provides rapid absorption and convenient dosing, while its haemostatic benefits are not shared by many other antidiuretic drugs.

Nocdurna should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Nocdurna is administered sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole, ensuring rapid absorption through the oral mucosa.

The most serious risks include severe hyponatremia, which can lead to seizures or coma, and rare thromboembolic events. Patients should be monitored closely for signs of low sodium and fluid overload, especially when taking interacting medications.

Nocdurna is contraindicated in patients with known hypersensitivity to desmopressin, those with uncontrolled hyponatremia, and individuals with severe renal impairment where water excretion is compromised. Caution is also advised for patients with uncontrolled heart failure or uncontrolled hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Desmopressin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT